Sagimet Biosciences Inc. develops clinical-stage fatty acid synthase (FASN) inhibitors for diseases tied to dysfunctional metabolic and fibrotic pathways. Company news centers on denifanstat, an oral FASN inhibitor studied in metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne, and TVB-3567, a second oral FASN inhibitor for acne.
Recurring updates include clinical and preclinical data presentations, FASCINATE-2 analyses, regulatory and license-partner developments, financial results, capital-structure disclosures, executive leadership changes, inducement grants, shareholder matters, and investor conference participation.
Sagimet Biosciences (Nasdaq: SGMT) reported that its Board’s Compensation Committee approved an inducement grant in connection with the hiring of three employees. On August 17, 2026, the company granted an aggregate 260,700 stock options to purchase Series A common stock under Nasdaq Rule 5635(c)(4).
According to Sagimet, the options were granted as a material inducement to employment, with an exercise price equal to the closing market price on August 17, 2026. Each option has a 10-year term and vests over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, subject to continued service.
Sagimet Biosciences (Nasdaq: SGMT) reported that the U.S. FDA has cleared its Investigational New Drug (IND) application and issued a “Study May Proceed” letter for a Phase 3 trial of denifanstat, an oral once-daily fatty acid synthase (FASN) inhibitor, in moderate to severe acne.
The U.S.-based Phase 3 study is on track to begin in the second half of 2026, enrolling about 800 patients, including approximately 450 adolescents. It will feature a 12-week randomized, double-blind period with well-accepted co-primary endpoints, followed by a 40-week open-label extension focused on long-term safety.
Sagimet Biosciences (Nasdaq: SGMT) reported second quarter 2026 results and clinical progress, highlighting its dermatology-focused strategy. A registrational Phase 3 trial of oral FASN inhibitor denifanstat in moderate to severe acne patients in the U.S. remains on track to start in the second half of 2026. A first‑in‑human Phase 1 trial of FASN inhibitor TVB‑3567 is ongoing, with plans for a Phase 2 acne trial by year‑end 2026 and development of a topical FASN inhibitor.
The company completed an underwritten equity financing in April 2026, raising $175.0 million in gross proceeds. Cash, cash equivalents and marketable securities totaled $257.6 million as of June 30, 2026, which Sagimet expects to fund operations through 2028, including denifanstat Phase 3 data readout and an NDA submission. Q2 2026 research and development expense was $11.5 million and general and administrative expense was $4.3 million, resulting in a net loss of $14.0 million, compared with a net loss of $10.4 million a year earlier. Sagimet was added to the Russell 3000 and Russell 2000 indexes and reported multiple scientific presentations on its FASN inhibitors.
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on therapeutics targeting dysfunctional metabolic and fibrotic pathways, announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA, including a fireside chat at 1:00 p.m. ET.
Sagimet Biosciences (Nasdaq: SGMT) has been added to the Russell 2000 and Russell 3000 indexes, effective June 29, 2026, as part of the 2026 Russell reconstitution.
The company plans to start a U.S. Phase 3 trial of denifanstat for moderate to severe acne in patients 12+ in the second half of 2026 and reports having capital to fund its programs, including this trial, through 2028.
Sagimet Biosciences (Nasdaq: SGMT) will participate in 1x1 investor meetings at the Leerink Partners Therapeutics Forum in Boston on July 15, 2026. The company also approved an inducement grant totaling 34,300 stock options to two newly hired employees under Nasdaq Listing Rule 5635(c)(4), with a ten-year term and four-year vesting schedule.
Sagimet Biosciences (Nasdaq: SGMT) presented two posters at EASL 2026 on its denifanstat/resmetirom combination for MASH. A Phase 1 open-label trial in 40 healthy adults showed the combo was generally well-tolerated, with no safety signals and rapid reductions in total and LDL cholesterol after two weeks of treatment.
The trial demonstrated target engagement for both agents via pharmacodynamic biomarkers. A separate preclinical poster in LDL receptor knockout MASH mice showed the combination improved liver histology and lipid lowering versus monotherapy, with transcriptomic analysis indicating enhanced anti-inflammatory, anti-fibrotic and metabolic regulatory effects.
Sagimet Biosciences (Nasdaq: SGMT) announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, in New York.
A fireside chat at 2:00 p.m. ET will be webcast live and archived for 90 days on Sagimet’s website.
Sagimet Biosciences (Nasdaq: SGMT) reported Q1 2026 results and key updates. The company completed a $175M equity financing in April 2026 and held $104.5M in cash, cash equivalents and marketable securities as of March 31, 2026.
According to Sagimet, the combined cash runway is expected to fund acne programs through 2028, including a planned Phase 3 denifanstat trial in moderate to severe acne in the U.S., targeted to start in H2 2026. An ongoing first-in-human Phase 1 trial of FASN inhibitor TVB-3567 supports plans for a Phase 2 acne trial in H2 2026. Q1 2026 R&D expense fell to $7.0M from $15.3M, and net loss narrowed to $10.7M from $18.2M year over year.
Sagimet Biosciences (Nasdaq: SGMT) will present new preclinical mechanism-of-action data on its FASN inhibitors for acne at the Society for Investigative Dermatology meeting in Chicago on May 15, 2026.
The data link reduced sebum-related lipids in human sebocytes to FASN inhibition and support a planned U.S. Phase 3 acne trial in 2H 2026.